<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230313057710N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-04-27</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Investigation of the Effect of topical application of amitriptyline and nortriptyline on irreversible pulpitis pain in teeth with failed pulpal anesthesia after a successful inferior alveolar nerve block</public_title>
      <acronym></acronym>
      <scientific_title>Investigation of the Effect of topical application of amitriptyline and nortriptyline on irreversible pulpitis pain in teeth with failed pulpal anesthesia after a successful inferior alveolar nerve block</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-07-13</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>45</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69175</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Each patient will allocated a code and the patients  assigned to three groups of 15 using a table of random numbers. In this way, intervention group 1 was assigned a two-digit code from 01 to 15, intervention group 2 was assigned a two-digit code from 16 to 30, and the control group was assigned a code from 31 to 45. Then, a number was randomly selected from the table of random numbers by placing a finger on it, and from the beginning of the selected number, the numbers were read in pairs in order. The numbers above 45 were removed, but the numbers between 01 and 45 were placed in one of 3 groups depending on the initial code assigned to each person in each group, Blinding description: Both patients and the dentist (researcher) were blind to the tube contents (double-blind design). Each Eppendorf tube was coded such that the dentist did not aware of its content. A coded Eppendorf tube was assigned to each patient by someone not involved in the study. After measuring the level of pain of patient during access cavity preparation and prior to pulp exposure, one Eppendorf tube randomly was assigned to each patient while the dentist  did not aware of type of intervention.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Pulpitis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: The diagnosis of irreversible pulpitis was confirmed by the heat and cold tests and presence of signs and symptoms of irreversible pulpitis such as severe long-lasting pain response to cold test, and pain during access cavity preparation (prior to pulp exposure). Patients showed signs of successful anesthetic injection 15 minutes after the IAN block injection of 2% lidocaine and 1:80,000 epinephrine (Darupakhsh Company, Tehran, Iran). 10 mg of amitriptyline (daroupakhsh company, Tehran, Iran) was prescribed. The colored coating of the tablets was removed and each tablet was powdered and mixed with 2 cc saline in an Eppendorf tube until a homogenous solution was obtained. The tubes were coded such that the dentist was blinded to the contents of each tube.  The tube content was applied on exposed dentin by a microbrush, and a cotton pellet was placed over it, followed by a cotton roll and then the patient was requested to bite on it for 3 minutes. After this time period, the dentist continued the process of access cavity preparation and the pain score was measured again. Pain was measured three times prior to the treatment onset, after the injection of anesthetic agent and initiation of access cavity preparation as the patient felt pain for the first time, and also after the application of medication using the McGill visual analog scale (VAS) and Wong-Baker Faces Pain Rating Scale (PRS). Intervention 2: Intervention group 2: 10 mg of Nortriptyline ( Sobhan darou  company, Tehran, Iran) was prescribed. The method of prescribing, intervention and data measurement were the same as the intervention 1. Intervention 3: Control group: Placebo including 10 mg starch was prescribed. The method of prescribing, intervention and data measurement were the same as the first intervention.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zahra Khosravani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezarjarib, the Endodontics Department, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran.</address>
        <city>Isfehan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>+98 31 3668 0048</telephone>
        <email>z.khosravani@dnt.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Armita Vali Sichani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezarjarib Avenu, the Endodontics Department, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran.</address>
        <city>Isfehan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>0098 3136680048</zip>
        <telephone>+98 81 7467 3461</telephone>
        <email>a.valisichani@dnt.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients requiring endodontic treatment of mandibular first molars showing the signs and symptoms of irreversible pulpitis and required treatment.
Who had evidence of successful IAN block.
Age 10-68 years</inclusion_criteria>
      <agemin>10 years</agemin>
      <agemax>68 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of hypersensitivity to TCAs, lidocaine or epinephrine
Lack of Systemic diseases (In according to self-report)
Pregnancy and nursing mothers
Patients who took systemic analgesics within 4-6 hours prior to dental visit,
Patients with complete anesthesia and no pain.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K04.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Pulpitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: The diagnosis of irreversible pulpitis was confirmed by the heat and cold tests and presence of signs and symptoms of irreversible pulpitis such as severe long-lasting pain response to cold test, and pain during access cavity preparation (prior to pulp exposure). Patients showed signs of successful anesthetic injection 15 minutes after the IAN block injection of 2% lidocaine and 1:80,000 epinephrine (Darupakhsh Company, Tehran, Iran). 10 mg of amitriptyline (daroupakhsh company, Tehran, Iran) was prescribed. The colored coating of the tablets was removed and each tablet was powdered and mixed with 2 cc saline in an Eppendorf tube until a homogenous solution was obtained. The tubes were coded such that the dentist was blinded to the contents of each tube.  The tube content was applied on exposed dentin by a microbrush, and a cotton pellet was placed over it, followed by a cotton roll and then the patient was requested to bite on it for 3 minutes. After this time period, the dentist continued the process of access cavity preparation and the pain score was measured again. Pain was measured three times prior to the treatment onset, after the injection of anesthetic agent and initiation of access cavity preparation as the patient felt pain for the first time, and also after the application of medication using the McGill visual analog scale (VAS) and Wong-Baker Faces Pain Rating Scale (PRS)</i_keyword>
      <i_keyword>Intervention group 2: 10 mg of Nortriptyline ( Sobhan darou  company, Tehran, Iran) was prescribed. The method of prescribing, intervention and data measurement were the same as the intervention 1.</i_keyword>
      <i_keyword>Control group: Placebo including 10 mg starch was prescribed. The method of prescribing, intervention and data measurement were the same as the first intervention.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>[The outcome variable is Irreversible pulpitis. Timepoint: Pain will measure three times including:  prior to the treatment onset, after the injection of anesthetic agent and initiation of access cavity preparation as the patient felt pain for the first time, and also after the application of medication. Method of measurement: McGill Visual Analogue Scale, Wong-Baker figure scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Isfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-06-26</approval_date>
        <contact_name>The ethics committee of Isfahan University of Medical  Sciences</contact_name>
        <contact_address>Hazar Jarib Ave, Isfahan University of Medical Sciences, Faculty of Dentistry, Isfahan, Iran Isfehan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
